Across TCGA pan-cancer cohorts, LINC02877 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated LINC02877 data layer compared with 13 for mass-spec protein.
The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher LINC02877 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LINC02877 expression acts as an unfavorable survival marker.
BLCA and UCEC are the cancer types where LINC02877 Mutation most reproducibly stratifies survival.